These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

634 related items for PubMed ID: 14679000

  • 1. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
    Li J, Hu P, Khawli LA, Epstein AL.
    Cancer Res; 2003 Dec 01; 63(23):8384-92. PubMed ID: 14679000
    [Abstract] [Full Text] [Related]

  • 2. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
    Liu A, Hu P, Khawli LA, Epstein AL.
    Clin Cancer Res; 2005 Dec 01; 11(23):8492-502. PubMed ID: 16322313
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth.
    Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Yamaguchi N, Yagita H, Okumura K.
    Cell Immunol; 2001 Dec 15; 214(2):194-200. PubMed ID: 12088418
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Li B, VanRoey M, Wang C, Chen TH, Korman A, Jooss K.
    Clin Cancer Res; 2009 Mar 01; 15(5):1623-34. PubMed ID: 19208793
    [Abstract] [Full Text] [Related]

  • 12. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H, Yoshizawa H, Yamaguchi Y, Ito K, Kagamu H, Suzuki E, Gejyo F, Hamada H, Arakawa M.
    J Immunol; 1999 Mar 15; 162(6):3574-82. PubMed ID: 10092816
    [Abstract] [Full Text] [Related]

  • 13. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.
    Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F.
    Eur J Immunol; 2004 Feb 15; 34(2):336-44. PubMed ID: 14768038
    [Abstract] [Full Text] [Related]

  • 14. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells.
    Sayers TJ, Brooks AD, Lee JK, Fenton RG, Komschlies KL, Wigginton JM, Winkler-Pickett R, Wiltrout RH.
    J Immunol; 1998 Oct 15; 161(8):3957-65. PubMed ID: 9780164
    [Abstract] [Full Text] [Related]

  • 15. Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models.
    Sadun RE, Hsu WE, Zhang N, Nien YC, Bergfeld SA, Sabzevari H, Lutsiak ME, Khawli L, Hu P, Epstein AL.
    J Immunother; 2008 Apr 15; 31(3):235-45. PubMed ID: 18317364
    [Abstract] [Full Text] [Related]

  • 16. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
    Hill HC, Conway TF, Sabel MS, Jong YS, Mathiowitz E, Bankert RB, Egilmez NK.
    Cancer Res; 2002 Dec 15; 62(24):7254-63. PubMed ID: 12499267
    [Abstract] [Full Text] [Related]

  • 17. Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer.
    Hu P, Arias RS, Sadun RE, Nien YC, Zhang N, Sabzevari H, Lutsiak ME, Khawli LA, Epstein AL.
    Clin Cancer Res; 2008 Jan 15; 14(2):579-88. PubMed ID: 18223234
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
    Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, Prell R, VanRoey MJ, Simmons AD, Jooss K.
    Clin Cancer Res; 2006 Nov 15; 12(22):6808-16. PubMed ID: 17121902
    [Abstract] [Full Text] [Related]

  • 20. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
    Jassar AS, Suzuki E, Kapoor V, Sun J, Silverberg MB, Cheung L, Burdick MD, Strieter RM, Ching LM, Kaiser LR, Albelda SM.
    Cancer Res; 2005 Dec 15; 65(24):11752-61. PubMed ID: 16357188
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.